Xin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xin Zhang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Yawei Shi
College of Life Sciences, Shanxi University, Taiyuan 030006, China
3 shared publications - Lihui Zhang
School of Energy and Environment, Anhui University of Technology, Maanshan 243002, Anhui Province, PR China
2 shared publications - Qianfeng Xiong
Department of Cardiology, Fengcheng People's Hospital The Affiliated Fengcheng Hospital of Yichun University Fengcheng Jiangxi province China
2 shared publications Shaohua Fan
Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Institute of Biotechnology, Shanxi University, Taiyuan 030006, China
2 shared publicationsChunlai Liang
Key Laboratory of Food Safety Risk Assessment of Ministry of Health, China National Center for Food Safety Risk Assessment, Beijing 100021, China
1 shared publication- Gang Wang
Division of Internal Medicine, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China
1 shared publication
Latest Publications
- 1 February 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (2) , 830-841.e14
Clinical Phenotypes of Patients Hospitalized for an Asthma Exacerbation: Prognostic Implications
- 1 February 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (2) , 830-841.e14
Clinical Phenotypes of Patients Hospitalized for an Asthma Exacerbation: Prognostic Implications
- 1 May 2020
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 52 (6) , 612-619
Glucagon-like peptide 1 reverses myocardial hypertrophy through cAMP/PKA/RhoA/ROCK2 signaling
Myocardial hypertrophy is a major pathological and physiological process during heart failure. Glucagon-like peptide 1 (GLP-1) is a glucagon incretin hormone released from the gut endocrine L-cells that has protective effects on various cardiovascular diseases, including hypertension, atherosclerosis, and myocardial hypertrophy. However, the protective mechanisms of GLP-1 in myocardial hypertrophy remain unclear. Here, we showed that the GLP-1 agonist liraglutide and dipeptidyl peptidase 4 inhibitor alogliptin decreased heart weight and cardiac muscle cell volume in spontaneously hypertensive rats (SHR). In H9C2 cell hypertensive models induced by angiotensin II, GLP-1 treatment reduced myocardial cell volume, inhibited the expressions of atrial natriuretic peptide, brain/B-type natriuretic peptide, β-myosin heavy chain, RhoA, and ROCK2, and decreased MLC and MYPT1 phosphorylation. When H9C2 cells were treated with H89, a PKA inhibitor, the inhibitory effect of GLP-1 disappeared, while the inhibitory role was enhanced under the treatment of Y-27632, a ROCK2 inhibitor. These results suggested that GLP-1 might reverse myocardial hypertrophy through the PKA/RhoA/ROCK2 signaling pathway.
- 1 May 2020
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 52 (6) , 612-619
Glucagon-like peptide 1 reverses myocardial hypertrophy through cAMP/PKA/RhoA/ROCK2 signaling
Myocardial hypertrophy is a major pathological and physiological process during heart failure. Glucagon-like peptide 1 (GLP-1) is a glucagon incretin hormone released from the gut endocrine L-cells that has protective effects on various cardiovascular diseases, including hypertension, atherosclerosis, and myocardial hypertrophy. However, the protective mechanisms of GLP-1 in myocardial hypertrophy remain unclear. Here, we showed that the GLP-1 agonist liraglutide and dipeptidyl peptidase 4 inhibitor alogliptin decreased heart weight and cardiac muscle cell volume in spontaneously hypertensive rats (SHR). In H9C2 cell hypertensive models induced by angiotensin II, GLP-1 treatment reduced myocardial cell volume, inhibited the expressions of atrial natriuretic peptide, brain/B-type natriuretic peptide, β-myosin heavy chain, RhoA, and ROCK2, and decreased MLC and MYPT1 phosphorylation. When H9C2 cells were treated with H89, a PKA inhibitor, the inhibitory effect of GLP-1 disappeared, while the inhibitory role was enhanced under the treatment of Y-27632, a ROCK2 inhibitor. These results suggested that GLP-1 might reverse myocardial hypertrophy through the PKA/RhoA/ROCK2 signaling pathway.
- Open Access
- 3 February 2020
- Published by Wiley in FEBS Letters
- Vol. 594 (10) , 1506-1516
Glucagon‐like peptide‐1 receptor undergoes importin‐α‐dependent nuclear localization in rat aortic smooth muscle cells
Glucagon‐like peptide 1 receptor (GLP‐1R) belongs to the family B of G‐protein‐coupled receptors (GPCRs) and has anti‐diabetic effects and cardiovascular functions. Classical GLP‐1R at the plasma membrane undergoes desensitization, internalization and is recycled back to the plasma membrane under the control of GLP‐1 in islet β‐cells. However, the subcellular localization of GLP‐1R in the vascular system remains unclear. Here, we find that GLP‐1R is localized in the nucleus of rat aortic smooth muscle cells (RASMCs) and in the tunica media. We identify a functional nuclear localization signal (NLS; 412‐442aa) at the C‐terminal region of GLP‐1R. Nuclear import of GLP‐1R is mediated by an importin‐α‐dependent pathway and regulated by phosphorylation of Ser416 in the NLS. Upon leaving the nucleus, GLP‐1R promotes cell proliferation in RASMCs. These findings may provide insights into the cardiovascular functions of GLP‐1R.
- 3 February 2020
- Published by Wiley in FEBS Letters
- Vol. 594 (10) , 1506-1516
Open AccessGlucagon‐like peptide‐1 receptor undergoes importin‐α‐dependent nuclear localization in rat aortic smooth muscle cells
Glucagon‐like peptide 1 receptor (GLP‐1R) belongs to the family B of G‐protein‐coupled receptors (GPCRs) and has anti‐diabetic effects and cardiovascular functions. Classical GLP‐1R at the plasma membrane undergoes desensitization, internalization and is recycled back to the plasma membrane under the control of GLP‐1 in islet β‐cells. However, the subcellular localization of GLP‐1R in the vascular system remains unclear. Here, we find that GLP‐1R is localized in the nucleus of rat aortic smooth muscle cells (RASMCs) and in the tunica media. We identify a functional nuclear localization signal (NLS; 412‐442aa) at the C‐terminal region of GLP‐1R. Nuclear import of GLP‐1R is mediated by an importin‐α‐dependent pathway and regulated by phosphorylation of Ser416 in the NLS. Upon leaving the nucleus, GLP‐1R promotes cell proliferation in RASMCs. These findings may provide insights into the cardiovascular functions of GLP‐1R.
- Open Access
- 23 October 2019
- Published by Wiley in Cardiology Research and Practice
- Vol. 2019, 1-8
GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents
GLP-1 is a new type of antidiabetic agent that possesses many beneficial effects. Although its cardiovascular actions have been widely examined, little is known about GLP-1’s effects on the rat coronary artery (RCA) or about the mechanisms underpinning these effects. Here, we report that GLP-1 inhibits depolarization- or thromboxane receptor agonist (U46619)-induced RCA contraction in a dosage-dependent manner. Vasorelaxation was attenuated by denuding the endothelium, L-NAME (nitric oxide synthase inhibitor), and glyburide (KATP channel blocker) but was not affected by indomethacin (cyclooxygenase inhibitor), iberiotoxin [Ca2+-activated K+ channel (KCa) blocker], or 4-aminopyridine (KV channel blocker). Furthermore, GLP-1 increased outward K+ currents by enhancing the KATP channel in rat coronary arterial smooth muscle cells (RCASMCs). These results show that GLP-1 is an endothelial-dependent vasospasmolytic agent in the RCA and imply that the relaxant effect is regulated by enhancing KATP rather than KV or KCa currents in RCASMCs.
- 23 October 2019
- Published by Wiley in Cardiology Research and Practice
- Vol. 2019, 1-8
Open AccessGLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents
GLP-1 is a new type of antidiabetic agent that possesses many beneficial effects. Although its cardiovascular actions have been widely examined, little is known about GLP-1’s effects on the rat coronary artery (RCA) or about the mechanisms underpinning these effects. Here, we report that GLP-1 inhibits depolarization- or thromboxane receptor agonist (U46619)-induced RCA contraction in a dosage-dependent manner. Vasorelaxation was attenuated by denuding the endothelium, L-NAME (nitric oxide synthase inhibitor), and glyburide (KATP channel blocker) but was not affected by indomethacin (cyclooxygenase inhibitor), iberiotoxin [Ca2+-activated K+ channel (KCa) blocker], or 4-aminopyridine (KV channel blocker). Furthermore, GLP-1 increased outward K+ currents by enhancing the KATP channel in rat coronary arterial smooth muscle cells (RCASMCs). These results show that GLP-1 is an endothelial-dependent vasospasmolytic agent in the RCA and imply that the relaxant effect is regulated by enhancing KATP rather than KV or KCa currents in RCASMCs.
- 1 January 2015
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 75, 146-150
A subchronic oral toxicity study on pyrroloquinoline quinone (PQQ) disodium salt in rats
- 1 January 2015
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 75, 146-150
A subchronic oral toxicity study on pyrroloquinoline quinone (PQQ) disodium salt in rats